Sec Form 13G Filing - Huang James @ CONNECT BIOPHARMA HLDGS LTD

Sec Form 13G Filing - Huang James filing for CONNECT BIOPHARMA HLDGS LTD (CNTB) - 2023-10-04

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Link

Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Connect Biopharma Holdings Limited

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

207523101**

(CUSIP Number)

October 2, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐	Rule 13d-1(b)

☒	Rule 13d-1(c)

☐	Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

**	There is no CUSIP number assigned to the Ordinary Shares of the Issuer (“Ordinary Shares”). CUSIP number 207523101 has been assigned to the American Depositary Shares of the Issuer (“ADSs”). Each ADS represents one Ordinary Share.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 207523101		Schedule 13G		Page 1 of 12


CUSIP No. 207523101		Schedule 13G		Page 2 of 12


CUSIP No. 207523101		Schedule 13G		Page 3 of 12


CUSIP No. 207523101		Schedule 13G		Page 4 of 12


CUSIP No. 207523101		Schedule 13G		Page 5 of 12


CUSIP No. 207523101		Schedule 13G		Page 6 of 12


CUSIP No. 207523101		Schedule 13G		Page 7 of 12


ITEM 1.	(a)	Name of Issuer:
		Connect Biopharma Holdings Limited (the “Issuer”).

	(b)	Address of Issuer’s Principal Executive Offices:

		12265 El Camino Real, Suite 350, San Diego, CA 92130.

ITEM 2.	(a)	Name of Person Filing:

		Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

		Panacea Opportunity Fund I, L.P.
		Panacea Opportunity Fund I GP Company, Ltd.
		Panacea Innovation Limited
		Panacea Venture Healthcare Fund II, L.P.
		Panacea Venture Healthcare Fund II GP Company, Ltd.
		James Huang

	(b)	Address of Principal Business Office:

		The business address of each of the Reporting Persons is c/o Maples Corporate Services Limited, Ugland House, Grand Cayman KY1-1104, Cayman Islands.

	(c)	Citizenship of each Reporting Person is:

		Mr. Huang is a citizen of the Republic of China. The remaining Reporting Persons are organized under the laws of the Cayman Islands.

	(d)	Title of Class of Securities:

		Ordinary Shares, par value $0.000174 per share (the “Ordinary Shares”). The Ordinary Shares are sold on the U.S. market as ADSs, each of which represents one Ordinary Share.

	(e)	CUSIP Number:

		207523101

ITEM 3.

Not applicable.


CUSIP No. 207523101		Schedule 13G		Page 8 of 12

ITEM 4.

Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of Ordinary Shares as of the date of this filing, based upon 55,064,947 Ordinary Shares outstanding as of June 30, 2023, as disclosed in the Issuer’s Report on Form 6-K, furnished with the Securities and Exchange Commission on September 12, 2023.


Reporting Person	Amount beneficially owned		Percent of class:			Sole power to vote or to direct the vote:		Shared power to vote or to direct the vote:		Sole power to dispose or to direct the disposition of:		Shared power to dispose or to direct the disposition of:
Panacea Opportunity Fund I, L.P.		0	0	%		0		0		0		0
Panacea Opportunity Fund I GP Company, Ltd.		0		0	%		0		0		0		0
Panacea Innovation Limited		5,995,000		10.9	%		0		5,995,000		0		5,995,000
Panacea Venture Healthcare Fund II, L.P.		5,995,000		10.9	%		0		5,995,000		0		5,995,000
Panacea Venture Healthcare Fund II GP Company, Ltd.		5,995,000		10.9	%		0		5,995,000		0		5,995,000
James Huang		5,995,000		10.9	%		0		5,995,000		0		5,995,000

Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein.

James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the Ordinary Shares directly reported herein, but each disclaims such beneficial ownership.

ITEM 5.

Ownership of Five Percent or Less of a Class.

This statement is being filed to report that, as of the date hereof, each of Panacea Opportunity Fund I, L.P. and Panacea Opportunity Fund I GP Company, Ltd. no longer beneficially own any Ordinary Shares.

ITEM 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

ITEM 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.


CUSIP No. 207523101		Schedule 13G		Page 9 of 12

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.

ITEM 9.

Notice of Dissolution of Group.

Not applicable.

ITEM 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


CUSIP No. 207523101		Schedule 13G		Page 10 of 12

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 4, 2023


Panacea Opportunity Fund I, L.P.
By: Panacea Opportunity Fund I GP Company, Ltd., its general partner
By: Panacea Innovation Limited, its sole owner

By:		/s/ James Huang
Name:		James Huang
Title:		Founding Managing Partner

Panacea Opportunity Fund I GP Company, Ltd.
By: Panacea Innovation Limited, its sole owner

By:		/s/ James Huang
Name:		James Huang
Title:		Founding Managing Partner

Panacea Innovation Limited

By:		/s/ James Huang
Name:		James Huang
Title:		Founding Managing Partner

Panacea Venture Healthcare Fund II, L.P.
By: Panacea Venture Healthcare Fund II GP Company, Ltd., its general partner
By: Panacea Innovation Limited, its sole owner

By:		/s/ James Huang
Name:		James Huang
Title:		Founding Managing Partner

Panacea Venture Healthcare Fund II GP Company, Ltd.
By: Panacea Innovation Limited, its sole owner

By:		/s/ James Huang
Name:		James Huang
Title:		Founding Managing Partner


CUSIP No. 207523101		Schedule 13G		Page 11 of 12

James Huang

/s/ James Huang


CUSIP No. 207523101		Schedule 13G		Page 12 of 12

LIST OF EXHIBITS


Exhibit No.		Description

99		Joint Filing Agreement.

Names of Reporting Persons

Panacea Opportunity Fund I, L.P.

Check the Appropriate Box if a Member of a Group

(a) ☐ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Cayman Islands